Vial, a clinical-stage biotech company, today announced growing enthusiasm among metabolic disease KOLs for Vial's INHBE siRNA, a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback